chromosome 11 open reading frame 68Genealiases: BLES03 · P5326
Q-omics provides the consensus-scored C11orf68 profile across patient tissues and cancer cell-line models. C11orf68 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, C11orf68 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, C11orf68 protein abundance shows 22,872 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UCS, HNSC, and PDAC as cancer lineages where C11orf68 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C11orf68 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C11orf68 survival associations across molecular data types. C11orf68 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C11orf68 RNA expression–survival associations across cancer types. High C11orf68 expression shows unfavorable associations in LIHC, ACC and BLCA, but favorable associations in UCS, LGG and UVM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for C11orf68 RNA expression.
This table summarizes C11orf68 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C11orf68. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C11orf68 shows lower tumor expression in UCEC and KICH and higher tumor expression in HNSC, KIRC, LIHC and KIRP. The HNSC box plot shows higher C11orf68 RNA expression in tumor versus normal tissue (log2 FC = +0.839, t-test p < 0.001).
This table shows molecular features associated with C11orf68 in patient tissues and cancer cell lines. In patient samples, C11orf68 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, C11orf68 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
